Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Late Breaking Abstract - Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial

Steven Greenberg, Gerald Horan, Brydon Bennett, Kate Blease, Ying Ye, Ada Azaryan, Francisco Ramirez-Valle, Ralph Ceres, Peter Schafer
European Respiratory Journal 2017 50: OA474; DOI: 10.1183/1393003.congress-2017.OA474
Steven Greenberg
1Celgene Corp, Summit, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerald Horan
1Celgene Corp, Summit, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brydon Bennett
2Celgene Corp, San Diego, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kate Blease
2Celgene Corp, San Diego, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying Ye
1Celgene Corp, Summit, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ada Azaryan
1Celgene Corp, Summit, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco Ramirez-Valle
1Celgene Corp, Summit, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph Ceres
1Celgene Corp, Summit, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Schafer
1Celgene Corp, Summit, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 50 no. suppl 61
DOI 
https://doi.org/10.1183/1393003.congress-2017.OA474

Published By 
European Respiratory Society
Print ISSN 
0903-1936
Online ISSN 
1399-3003
History 
  • Published online December 6, 2017.

Copyright & Usage 
Copyright ©the authors 2017

Author Information

  1. Steven Greenberg1,
  2. Gerald Horan1,
  3. Brydon Bennett2,
  4. Kate Blease2,
  5. Ying Ye1,
  6. Ada Azaryan1,
  7. Francisco Ramirez-Valle1,
  8. Ralph Ceres1 and
  9. Peter Schafer1
  1. 1Celgene Corp, Summit, United States of America
  2. 2Celgene Corp, San Diego, United States of America

Article usage

Article usage: December 2017 to March 2021

AbstractFullPdf
Dec 20172800
Jan 20184200
Feb 20186400
Mar 201810100
Apr 20184100
May 20185100
Jun 20185400
Jul 20189000
Aug 20189200
Sep 20187700
Oct 20184700
Nov 20187600
Dec 20187900
Jan 20198600
Feb 201910100
Mar 201913800
Apr 201916100
May 201913600
Jun 201911900
Jul 201920400
Aug 201928500
Sep 201928600
Oct 201930800
Nov 201919900
Dec 201916000
Jan 202010700
Feb 20209400
Mar 202010300
Apr 20206000
May 202010700
Jun 20208900
Jul 20207800
Aug 20207600
Sep 20209000
Oct 20208200
Nov 20208800
Dec 20207000
Jan 20217600
Feb 20219500
Mar 20218900

Altmetrics

Previous
Back to top
Vol 50 Issue suppl 61 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Late Breaking Abstract - Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Late Breaking Abstract - Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial
Steven Greenberg, Gerald Horan, Brydon Bennett, Kate Blease, Ying Ye, Ada Azaryan, Francisco Ramirez-Valle, Ralph Ceres, Peter Schafer
European Respiratory Journal Sep 2017, 50 (suppl 61) OA474; DOI: 10.1183/1393003.congress-2017.OA474

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Late Breaking Abstract - Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial
Steven Greenberg, Gerald Horan, Brydon Bennett, Kate Blease, Ying Ye, Ada Azaryan, Francisco Ramirez-Valle, Ralph Ceres, Peter Schafer
European Respiratory Journal Sep 2017, 50 (suppl 61) OA474; DOI: 10.1183/1393003.congress-2017.OA474
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • An epidemiological study on the effect of age, sex and comorbidities on the clinical course of idiopathic pulmonary fibrosis
  • The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis
  • The programmed death of alveolar lymphocytes is elevated in idiopathic pulmonary fibrosis (IPF). The plausible explanation of well-known bronchoalveolar lavage cytological findings?
Show more Diffuse Parenchymal Lung Disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society